Corient Private Wealth LLC Trims Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Corient Private Wealth LLC decreased its position in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 3.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,419 shares of the biotechnology company’s stock after selling 396 shares during the period. Corient Private Wealth LLC’s holdings in Viking Therapeutics were worth $500,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Blue Trust Inc. lifted its holdings in Viking Therapeutics by 75.9% in the fourth quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 309 shares during the last quarter. YANKCOM Partnership acquired a new stake in Viking Therapeutics during the fourth quarter worth $33,000. S.A. Mason LLC raised its position in Viking Therapeutics by 20.0% in the fourth quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 300 shares during the period. Wolff Wiese Magana LLC purchased a new stake in Viking Therapeutics in the fourth quarter valued at $75,000. Finally, AlphaQuest LLC grew its holdings in shares of Viking Therapeutics by 79.4% during the 4th quarter. AlphaQuest LLC now owns 1,938 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 858 shares during the period. Hedge funds and other institutional investors own 76.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Piper Sandler reduced their price objective on shares of Viking Therapeutics from $74.00 to $71.00 and set an “overweight” rating on the stock in a report on Thursday, February 6th. B. Riley reiterated a “buy” rating and set a $96.00 price target (down from $109.00) on shares of Viking Therapeutics in a research report on Friday, February 7th. Maxim Group decreased their price objective on shares of Viking Therapeutics from $120.00 to $70.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Citigroup began coverage on shares of Viking Therapeutics in a report on Friday, February 7th. They issued a “neutral” rating and a $38.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and set a $102.00 price target on shares of Viking Therapeutics in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Viking Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $95.18.

Insider Buying and Selling

In other news, CFO Greg Zante sold 50,309 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $42.75, for a total value of $2,150,709.75. Following the transaction, the chief financial officer now owns 165,259 shares in the company, valued at approximately $7,064,822.25. This represents a 23.34 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Marianna Mancini sold 54,215 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $42.75, for a total value of $2,317,691.25. Following the sale, the chief operating officer now owns 374,134 shares of the company’s stock, valued at approximately $15,994,228.50. The trade was a 12.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 299,014 shares of company stock worth $12,782,849 over the last 90 days. 4.70% of the stock is owned by insiders.

Viking Therapeutics Trading Down 1.8 %

NASDAQ:VKTX opened at $25.65 on Friday. Viking Therapeutics, Inc. has a 12-month low of $24.41 and a 12-month high of $82.00. The firm has a market cap of $2.88 billion, a PE ratio of -25.65 and a beta of 0.90. The stock has a fifty day moving average price of $30.29 and a 200 day moving average price of $46.60.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same quarter last year, the firm posted ($0.25) earnings per share. Equities analysts forecast that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.

Viking Therapeutics Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.